Health Economics›Mediastinal gray-zone lymphoma›Relapsed or refractory

Relapsed or refractory

Mediastinal gray-zone lymphoma · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Brentuximab vedotin monotherapy Variant #01	—	R 85 244	21d	~25.6 mo	—	~38	~R 3 239 268 PFS proxy · indirect	2

1 of 1 regimen shown